secwatch.observer — SEC 8-K summary
======================================

Issuer:     REVELATION BIOSCIENCES, INC. (REVB)
CIK:        0001810560
Form:       8-K
Filed at:   2024-08-09T23:59:59+00:00
Accession:  0000950170-24-094788
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Revelation Biosciences Q2 net loss $8.4M; cash $12.1M, plans Phase 1b
---------------------------------------------------------------------

- Net loss for Q2 2024 of $8.4M ($5.13 per share) vs $1.4M loss in Q2 2023.
- Net loss for H1 2024 of $11.1M ($8.13 per share) vs net income of $4.7M in H1 2023.
- Cash and equivalents $12.1M as of June 30, 2024, up from $12.0M at Dec 31, 2023.
- Completed Phase 1 dosing of Gemini; safety endpoint met with biomarker activity.
- Phase 1b study in CKD patients expected to start in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024094788/0000950170-24-094788-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1810560/000095017024094788/revb-20240809.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-094788

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer